Hoxton Ventures

"One reason for the recent decline in the uptake of rapid Covid-19 tests is the sampling technique – it’s currently very uncomfortable and difficult for people to use. We need to take the pain out of mass testing if we’re to return to normal to minimise the disruption caused by future COVID-19 outbreaks, whether in offices, schools or hospitality venues. That’s why we’ve built supportive bio security technology that sits alongside the test, allowing users to generate their own unique QR codes to facilitate safe venue entry."

"Today, we’ve developed the world’s first Engineering-Grade AR solution helping construction teams identify errors in real-time, but really that’s just the start of our journey. The next phase is Assisted Reality, where our spatial computing technology will have the intelligence to automatically detect and report issues in the field. And ultimately, the goal is builders building from holograms. Our vision of developing world changing products aligns with Octopus Ventures’ mission of investing in companies that are powering the next industrial revolution. We look forward to building history."

"At Fy!, we're passionate about building a new way to shop for all the products people care about. We're thrilled to add Hoxton Ventures to the team and chose them due to their strong track record in supporting UK startups scale globally. We will be using this latest investment to continue to grow internationally – the US sales already make up over a third of Fy!'s revenue – by expanding our assortment there and launching Fy! in a number of large European markets."

"Our sole focus at Peptone is to embrace experimental failure and, in fact, acknowledge it as an absolutely vital stage in the process of getting the design of protein-based medicines right. Great science is always born out of failure. The reality is that drug discovery in Big Pharma sees only a small fraction of protein based drugs pass the preclinical stages due to their complexity. Pharma, just like any industry, is subject to the ‘power law’. A small number of innovative drugs generate disproportional benefits to patients and outsized capital returns. We are working on shifting this failure-to-success ratio in a meticulously predictable and repeatable way using the best computational methods and scalable data science. Only last week one of our clients produced a monoclonal antibody for which our platform suggested seven radical mutations. The said therapeutic protein got vastly improved. The probability of a human researcher being able to engineer this type of change is equal to 1/1,280,000,000. In layman terms you are four times more likely to win the Powerball lottery than to spontaneously find the solution our platform has identified in less than ten days. The business of protein therapeutics is a huge industry and as we grow and further develop our supercomputing capacity we can help make significant progress in the time to market for much sought-after protein-based treatments."

"This is one of the most highly-anticipated stages of our business and a really important step. We’ve spent time talking to our customers and industry specialists, and seen huge enthusiasm for DK-One’s potential. Now up and running, this will be the first time we can use a pre-production machine to demonstrate the DK-One’s commercial and nutritional benefits in the real world and thus demonstrate our vision for the future of food. I am proud of our amazing team for the work they’ve done to get this far this quickly, despite the challenges of the pandemic. We are all really excited to begin fulfilling our customer’s expectations."